CLP 1001

Drug Profile

CLP 1001

Alternative Names: CLP; CLP1001

Latest Information Update: 12 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sorbent Therapeutics
  • Class Heart failure therapies; Polymers
  • Mechanism of Action Sodium-potassium-chloride symporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Heart failure

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 12 Jan 2016 No recent reports on development identified - Phase-II for Heart failure in USA, Argentina, Israel (PO)
  • 25 Jun 2015 No recent reports of development identified - Phase-II for Heart failure in Moldova, Armenia and Georgia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top